GSK fined £37m for ‘anti-competitive’ conduct


GSK fined £37m for ‘anti-competitive’ conduct

360b /

GSK has been fined more than £37 million ($53 million) by the UK government for “anti-competitive conduct” in relation to ‘pay for delay’ deals centring on anti-depressant drug Seroxat (paroxetine).

GSK, anti-competition, generic, Seroxat, patent, patent infringement, pay-for-delay, GUK, Alpharma, paroxetine, Competition and Markets Authority